These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 33504449)

  • 1. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
    Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
    Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
    Bailey S; Singh A; Azadian R; Huber P; Blum M
    Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
    Pierce CE; Bouri K; Pamer C; Proestel S; Rodriguez HW; Van Le H; Freifeld CC; Brownstein JS; Walderhaug M; Edwards IR; Dasgupta N
    Drug Saf; 2017 Apr; 40(4):317-331. PubMed ID: 28044249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
    Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
    Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants.
    Wong CK; Ho SS; Saini B; Hibbs DE; Fois RA
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):731-7. PubMed ID: 26017154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights October - December 2016.
    Rose BJ
    Hosp Pharm; 2017 Feb; 52(2):153-154. PubMed ID: 28321144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights July-September 2016.
    Rubio T
    Hosp Pharm; 2016 Dec; 51(11):941-943. PubMed ID: 28057955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events.
    Li W; Wertheimer A
    Innov Pharm; 2023; 14(1):. PubMed ID: 38035313
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
    Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
    Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
    Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
    JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.